{"id":389347,"date":"2020-11-30T07:03:36","date_gmt":"2020-11-30T12:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389347"},"modified":"2020-11-30T07:03:36","modified_gmt":"2020-11-30T12:03:36","slug":"syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/","title":{"rendered":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WALTHAM, Mass.<\/span>, Nov. 30, 2020<\/span> \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cGVHD) on Sunday, December 6, 2020<\/span> at 2:00 p.m. E.T.<\/span> The event will take place following an oral presentation<\/a> highlighting updated data from the Company’s Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with cGVHD at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. <\/p>\n

The conference call and webcast will include a summary of the ASH 2020 data presentation, as well as a review of select patient case studies, and a discussion on how axatilimab may fit into the current and evolving cGVHD treatment landscape. The event will feature lead author of the ASH 2020 presentation, Mukta Arora<\/span>, M.D., M.S., Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota<\/span> Medical School, and co-author, Geoffrey Hill<\/span>, M.D., Jos\u00e9 Carreras\/E. Donnall Thomas Endowed Chair for Cancer Research and Director of The Immunotherapy Integrated Research Center at Fred Hutchinson Cancer Research Center. <\/p>\n

\n Conference Call and Webcast Details:<\/b>\n <\/p>\n

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at\u00a0www.syndax.com<\/a>. Alternatively, the conference call may be accessed through the following:<\/p>\n

\n Conference ID<\/b>: 8698086
Domestic Dial-in Number<\/b>: (855) 251-6663
International Dial-in Number<\/b>: (281) 542-4259
Live Webcast<\/b>:\u00a0https:\/\/edge.media-server.com\/mmc\/p\/ddupdib6<\/a><\/p>\n

For those unable to participate in the live conference call or webcast, a replay will be available on the Investors section of the Company’s website,\u00a0www.syndax.com<\/a>.<\/p>\n

\n About Syndax Pharmaceuticals, Inc. <\/b>\n <\/p>\n

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin\u2013MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit\u00a0www.syndax.com<\/a>\u00a0or follow the Company on\u00a0Twitter<\/a>\u00a0and\u00a0LinkedIn<\/a>.\u00a0<\/p>\n

\n Syndax’s Cautionary Note on Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax’s product candidates, and the potential use of our product candidates to treat various cancer indications. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of Syndax’s collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n

\n Syndax Contacts<\/b>\n <\/p>\n

Investor Contact
Melissa Forst<\/span>
Argot Partners
melissa@argotpartners.com<\/a>\u00a0
Tel 212.600.1902<\/p>\n

Media Contact
Ted Held<\/span>
ted.held@gcihealth.com<\/a>
Tel 212.798.9842<\/p>\n

SNDX-G<\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts-301181335.html<\/a><\/p>\n

SOURCE Syndax Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire WALTHAM, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cGVHD) on Sunday, December 6, 2020 at 2:00 p.m. E.T. The event will take place following an oral presentation highlighting updated data from the Company’s Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with cGVHD at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The conference call and webcast will include a summary of the ASH 2020 data presentation, … <\/p>\n

Continue reading “Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389347","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSyndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire WALTHAM, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cGVHD) on Sunday, December 6, 2020 at 2:00 p.m. E.T. The event will take place following an oral presentation highlighting updated data from the Company’s Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with cGVHD at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The conference call and webcast will include a summary of the ASH 2020 data presentation, … Continue reading "Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T12:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts\",\"datePublished\":\"2020-11-30T12:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/\"},\"wordCount\":724,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE05630&sd=2020-11-30\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/\",\"name\":\"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE05630&sd=2020-11-30\",\"datePublished\":\"2020-11-30T12:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE05630&sd=2020-11-30\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE05630&sd=2020-11-30\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/","og_locale":"en_US","og_type":"article","og_title":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk","og_description":"PR Newswire WALTHAM, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cGVHD) on Sunday, December 6, 2020 at 2:00 p.m. E.T. The event will take place following an oral presentation highlighting updated data from the Company’s Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with cGVHD at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The conference call and webcast will include a summary of the ASH 2020 data presentation, … Continue reading \"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T12:03:36+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts","datePublished":"2020-11-30T12:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/"},"wordCount":724,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/","name":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30","datePublished":"2020-11-30T12:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE05630&sd=2020-11-30"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-axatilimab-conference-call-and-webcast-featuring-two-cgvhd-experts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389347"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}